NUCLEIC ACID FOR DIAGNOSING LIVER CANCER AND PROTEIN DETECTION KIT

• Main Authors: WANG, Yupeng, JIANG, Ruijingfang, ZHOU, Jian, SUN, Jianlong, ZHU, Shida, GUO, Dezhen, YANG, Xinrong, LI, Zhilong, PENG, Jiaxi, HUANG, Ao, FAN, Jia, WANG, Yuying
• Format: Patent
• Language: Chinese; English; French
• Published: 19.05.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

Disclosed is a nucleic acid detection kit for diagnosing liver cancer. The present invention provides a use of the combination of "methylated OTX1 gene, methylated HIST1H3G gene, alpha-fetoprotein and abnormal prothrombin" as combined markers in the following: diagnosing or screening cancer, warning about cancer before clinical symptoms, and distinguishing or assisting in distinguishing cancer from benign lesions. In the present invention, the methylation of OTX1 gene and HIST1H3G gene and the contents of alpha-fetoprotein and abnormal prothrombin are used as combined markers for liver cancer screening. By detecting the methylation levels of OTX1 gene and HIST1H3G gene and the contents of alpha-fetoprotein and abnormal prothrombin and analyzing obtained data, the possibility of a subject suffering from liver cancer can be predicted, and thus the purpose of screening liver cancer in the general population or in groups at high risk of liver cancer can be achieved. L'invention concerne un kit de détection d'acid